FRS2 and neoplasm: It binds to the third immunoglobulin region of the FGFR2b receptor, blocks the activation of FGFR2b and downstream FRS2 (fibroblast growth factor receptor substrate 2) phosphorylation, as well as enhances the antibody-dependent cellular toxicity against tumor cells that express FGFR2b [124].